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Abstract
BACKGROUND: Radiolabelled prostate-specific membrane antigen (PSMA)-based PET/CT is a whole-body imaging technique 
currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the 
neovasculature of many other solid tumours. The aim of this review is to evaluate the possible diagnostic role of radiolabelled 
PSMA PET/CT in breast cancer.
MATERIAL AND METHODS: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane 
Library databases was conducted to find relevant published articles about the diagnostic performance of radiolabelled PSMA 
PET/CT in breast cancer.
RESULTS: The comprehensive computer literature search revealed 652 articles. On reviewing the titles and abstracts, 640 articles 
were excluded because the reported data were not within the field of interest of this review. Twelve articles were selected and 
retrieved in full-text version; no additional study was found when screening the references of these articles. In total, 12 articles 
were included in the systematic review.
CONCLUSIONS: Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of 
radiolabelled PSMA in this setting and its possible position in the diagnostic flow-chart.
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Introduction
Radiolabelled Gallium-68 (68Ga) of Fluorine-18 (18F) pros-
tate-specific membrane antigen (PSMA)-based positron emission 
tomography/computed tomography (PET/CT) are whole-body 
imaging techniques currently performed to detect prostate cancer 
(PCa) lesions. The main diagnostic field of PSMA-based imaging 
is the whole body primary staging of intermediate and high-risk 
PCa or PCa restaging after biochemical disease relapse (rising 
prostate-specific antigen levels) in patients with prior radical pros-
tatectomy or external beam radiation [1–3].
Human PSMA is a zinc containing metalloenzyme (750 
amino acids) with a unique 3-part structure composed of a large 
extracellular domain, a transmembrane portion, and an intracel-
lular component. PSMA has recently emerged as a target for 
radionuclide imaging and treatment of PCa as this protein is signifi-
cantly overexpressed by most PCa cells [4–14]. High expression of 
PSMA in PCa and upon ligand-binding internalization of PSMA by 
clathrin-coated pits and subsequent endocytosis makes it a use-
ful target for diagnostic and therapeutic applications in nuclear 
medicine. However, PSMA has been demonstrated to be expressed 
by the neovasculature of many solid tumours (for example colon, 
gastric, lung, gliomas/glioblastomas, adrenal, bladder, renal cell 
carcinoma), in some non-neoplastic conditions and also as inci-
dental findings in other organs like thyroid [6–14]. High expression 
of PSMA and upon ligand-binding internalization of PSMA by clath-
rin-coated pits and subsequent endocytosis makes it a useful target 
for diagnostic and therapeutic applications in nuclear medicine.
The aim of this literature systematic review is to evaluate 
the possible diagnostic role of radiolabelled PSMA PET/CT in 
patients with breast cancer and to expand the knowledge about 
PSMA uptake in cancers in addiction to prostate one focusing in 
particular on breast cancer.
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A comprehensive literature search of the PubMed/MEDLINE, 
Scopus, Embase and Cochrane Library databases was con-
ducted to find published articles about the role of radiolabelled 
PSMA PET/CT in breast cancer. We used a search algorithm that 
was based on a combination of the terms: a) ‘‘PSMA” OR “pros-
tate-specific membrane antigen” AND b) “breast”. No beginning 
date limit was used; the search was updated until July 30th 2019. 
Only articles in the English language were selected, pre-clinical 
or not in vivo studies, conference proceedings, editorials and 
reviews were excluded. To expand our search, references of the 
retrieved articles were also screened for additional studies. All 
literature studies collected were managed using EndNote Web 3.3.
Study selection
All articles reporting patients with breast cancer evaluated by 
radiolabelled PSMA PET/CT in the clinical setting were eligible for 
inclusion. Two researchers  independently reviewed the titles and 
abstracts of the retrieved articles. The same two researchers then 
independently reviewed the full-text version of the remaining ar-
ticles to determine their eligibility for inclusion.
Data abstraction
For each included study, information was collected concerning 
the basic study (author names, year of publication, country of origin, 
type of study) and PET device used (PET/CT or PET), number of 
patients evaluated and final diagnosis. The main findings of the 
articles included in this review are reported in the Results.
Results
Literature search
The comprehensive computer literature search revealed 652 ar-
ticles (Fig. 1). On reviewing the titles and abstracts, 640 articles were 
excluded because the reported data were not within the field of 
interest of this review. Twelve articles were selected and retrieved 
in full-text version [15–26]; no additional study was found when 
screening the references of these articles. In total, 12 articles were 
included in the systematic review [15–26].
Qualitative analysis (systematic review)
Findings of several studies have documented that radiolabelled 
PSMA PET/CT imaging may identify breast cancer and its metas-
tases. The characteristics of the studies and results are briefly 
presented in Table 1 and Table 2.
Discussion
Imaging of breast cancer has always been challenging for 
the nuclear medicine physicians and the radiologists. The PSMA 
is a type II transmembrane protein physiologically, mapped to 
chromosome 11q14, expressed by prostate tissue and signifi-
cantly over-expressed by most PCa cells. However, PSMA is not 
solely expressed by prostate tissue [6–14]. Importantly, PSMA 
over-expression also occurs in pathophysiologic processes other 
than PCa, especially in the neovasculature of multiple malignancies. 
Among the most common non-PCa to demonstrate PSMA expres-
sion are breast, lung, colorectal, and renal cell carcinoma; in par-
ticular, it has long been hypothesized and documented the PSMA 
expression in breast carcinomas [27–29]. These findings suggest 
that PSMA may have broader potential as a tumour-associated 
neo-vascular target in addition to one that is tumour-specific 
(prostate) and consequently the insight that radiolabelled PSMA 
PET/CT could be suitable and useful in evaluating breast cancer. 
In the study by Wernicke et al. [29] is demonstrated that PSMA 
expression in the neovasculature of primary breast cancers (74%), 
as well as, distant metastatic disease (100%) is largely restricted 
to endothelial cells within the pathologically defined tumour area.
So far, the clinical (in vivo) use of radiolabelled PSMA PET/CT 
is only preliminary explored; in fact, from the results of our re-
view only 12 articles have been found, 11 of which were case 
reports [15–23, 25, 26].
Considering the 11 cases reports, in all 11 patients radiolabelled 
PSMA PET/CT was positive identifying primary or metastatic lesions, 
despite in two cases of male patients the radiolabelled PSMA uptake 
was determined by gynecomastia [16, 23] and in one case by pseu-
doangiomatous stromal hyperplasia [25]. Interestingly, the number 
of male patients who underwent radiolabelled PSMA PET/CT and in 
which a breast uptake was identified was not negligible (2 out of 5); 
breast cancer was incidentally diagnosed in 2/5 male patients [15, 
17] and benign lesions in 3/5 [16, 23, 25].
Only the study by Sathekge et al. [24] was a prospective evalu-
ation enrolling 19 female patients; 68Ga-PSMA PET/CT imaging 
was performed in 9 “de novo” diagnosed breast carcinoma patients, 
in 5 patients presenting with a loco-regional recurrence of breast 
carcinoma, and in a pre-treatment metastasized setting in another 5 
patients. They documented a robust expression of PSMA by breast 
cancer lesions as evidenced using 68Ga-PSMA PET/CT imaging and 
Figure 1. Flow-chart of the search strategy
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the absence of PSMA expression on normal vascular endothelium 
as well as its limited expression on the luminal side of the intestinal 
epithelium (which is not accessible via the vasculature); these 
facts have suggested that PSMA could be an interesting potential 
target for antiangiogenic therapy of breast carcinoma.
Considering the very low number of reports and patients ana-
lyzed in literature, no high-quality evidence could be drawn about 
the role of radiolabelled PSMA PET/CT in breast cancer but 
this evaluation can be helpful in better understanding the diagnostic 
potential of the tracer and the underlying metabolic mechanisms; 
further studies and prospective large studies are desirable to 
clarify the real diagnostic role of radiolabelled PSMA in this field 
and its possible position in the diagnostic flow-chart. However, 
the available literature data demonstrate that breast cancers are 
radiolabelled PSMA-avid tumours. These insights, if confirmed, 
could open up the way to possible future use of radiolabelled PSMA 
PET/CT in this tumours. 
Conclusions
Despite few studies are currently available, radiolabelled PSMA 
is not specific for the prostate, as several benign and malignant 
entities have been reported by imaging and histologic studies to 
show a relevant expression, especially in tumour-associated en-
dothelial cells. Radiolabelled PSMA imaging seems to be useful 
in analysing breast cancer despite further studies enrolling larger 
population are desirable to clarify the real clinical and diagnostic 
role of radiolabelled PSMA PET/CT and its possible position in the 
diagnostic flow-chart.
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Table 1. Characteristics of studies about radiolabelled PSMA
First author Ref. Year N.Pts Gender Type of study Country Device Isotope
Polverari 15 2019 1 M CR Italy PET/CT 68Ga
Daglioz Gorur 16 2018 1 M CR Turkey PET/CT 68Ga
Kumar 17 2018 1 M CR India PET/CT 68Ga
Malik 18 2018 1 F CR in CS India PET/CT 68Ga
Medina-Ornelas 19 2018 1 F CR Mexico PET/CT 68Ga
Parihar 20 2018 1 F CR India PET/CT 68Ga
Passah 21 2018 1 F CR India PET/CT 68Ga
Tolkach 22 2018 1 F CR in study Germany PET/CT 68Ga
Sasikumar 23 2017 1 M CR India PET/CT 68Ga
Sathekge 24 2017 19 F P South Africa PET/CT 68Ga
Malik 25 2016 1 M CR India PET/CT 68Ga
Sathekge 26 2015 1 F CR South Africa PET/CT 68Ga
Ref. — reference; N.Pts — cases examined; P — prospective; CR — case report; CS — case series; M — male; F — female
Table 2. PSMA results and final diagnosis
First author Ref. N.Pts PET/CT positive Final diagnosis Gold standard  final diagnosis
Polverari 15 1 1 Invasive ductal breast cancer, nonspecial type Histology
Daglioz Gorur 16 1 1 Gynecomastia   US
Kumar 17 1 1 Infiltrating ductal carcinoma Fine-needle aspiration cytology/histology
Malik 18 1 1 Breast cancer  MM NA
Medina-Ornelas 19 1 1 Brain MM from breast cancer Histology
Parihar 20 1 1 Triple-negative signet ring cell adenocarcinoma 
(primary lesion and MM
Histology
Passah 21 1 1 MM from triple-negative breast carcinoma Histology
Tolkach 22 1 1 MM from triple-negative breast cancer and local 
persistence of disease
Histology
Sasikumar 23 1 1 Gynecomastia US and Mx
Sathekge 24 19 19 Breast cancer  (primary site, local relapse or MM)* Histology ^^/ clinical
Malik 25 1 1 Pseudoangiomatous stromal hyperplasia Histology
Sathekge 26 1 1 MM from breast cancer Clinical/18FDG-PET/CT
Ref. — reference; N.Pts — cases examined; NA — not available; US — ultrasonography; MM — metastases; Mx — mammography; * — 13 ductal, 2 lobular, 1 neuroendocrine, 3 NA; ^^ — 
for patients with “de novo” diagnosed breast carcinoma
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